Tocagen, a clinical-stage, cancer-selective gene therapy company, is developing first-in-class, broadly applicable product candidates designed to activate a patient’s immune system against their own cancer. Tocagen is developing its lead investigational product regimen, Toca 511 & Toca FC, initially for the treatment of recurrent high grade glioma (rHGG), an area of huge unmet need. A randomized, controlled P3 trial of Toca 511 & Toca FC in patients with rHGG is ongoing and is designed as a potential registration trial. Tocagen is also evaluating Toca 511 & Toca FC in other solid tumors.